Background: Actinium-225 ( 225 Ac, t 1/2 = 9.9 d) is a promising candidate radionuclide for use in targeted alpha therapy (TAT), though the currently limited global supply has hindered the development of a suitable Ac-chelating ligand and 225 Ac-radiopharmaceuticals towards the clinic. We at TRIUMF have leveraged our Isotope Separation On-Line (ISOL) facility to produce 225 Ac and use the resulting radioactivity to screen a number of potential 225 Acradiopharmaceutical compounds.
Background
Due to recent clinical results demonstrating the exceptional ability of 225 Ac-radiopharmaceuticals for the treatment of late stage castration resistant prostate cancer (Sathekge et al. 2018; Kratochwil et al. 2016; Kratochwil et al. 2018) , considerable efforts within the field of nuclear medicine have been directed towards development of new radiopharmaceuticals for targeted alpha therapy (TAT) containing 225 Ac or other suitable alpha-emitting radionuclides (Poty et al. 2018a; Poty et al. 2018b; Seidl 2014; Kim and Brechbiel 2012; 11th International Symposium on Targeted Alpha Therapy (TAT11), 2019; Elgqvist et al. 2014; Morgenstern et al. 2018; Baidoo et al. 2013) . Despite these promising preliminary findings, the progression of 225 Ac drugs towards the clinic has been obstructed by the limited radionuclide supply and the limited investigation of radiochemical protocols for chelating 225 Ac III under mild conditions. Currently, the total global supply of 225 Ac is approximately 63 GBq (1.7 Ci) per year, slowing clinical trials and resulting in high costs that make 225 Ac inaccessible to many researchers.
The reader is referred to the following reviews for a more detailed overview of 225 Ac supply (Robertson et al. 2018; Engle 2018) . Moreover, the absence of a stable surrogate isotope makes the study of actinium chemistry particularly challenging, and only very recently have insights into the fundamental chemical properties and coordination preferences of the actinide appeared in the literature (Ferrier et al. 2017; Ferrier et al. 2016) . The tetraaza macrocycle DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, N 4 O 4 ), is currently the "gold standard" in 225 Ac chelation, despite the chelating ligand's sub-optimal properties for encapsulating this large actinide. DOTA forms kinetically inert complexes with 225 Ac, albeit at a cost of slow radiolabeling kinetics which requires heating to elevated temperatures and extended reaction times (Ramogida and Orvig 2013; Price and Orvig 2014) . The requirement to heat the current gold standard DOTA, above physiological temperatures for extended periods to facilitate incorporation of the 225 
Ac
III ion is adequate yet not ideal for small molecule or peptide bioconjugates that can withstand such temperatures but results in denaturing of sensitive biomolecules such as antibodies (Maguire et al. 2014; McDevitt et al. 2002) . Consequently, two-step radiolabeling methods are often required for antibody radiolabeling. For example, the DOTA-isothiocyanate (DOTA-NCS) bifunctional chelate can be radiolabeled with 225 Ac at elevated temperatures first, followed by conjugation to the antibody at mild temperature, unfortunately the hydrolysis of the isothiocyanate in the first step results in low radiochemical yields (8-11%) (McDevitt et al. 2002) . Recently, Poty et al. have demonstrated that a DOTA-tetrazine bifunctional chelate can be radiolabeled in a two-step method to a transcyclooctene-modified antibody by exploiting the facile inverse electron-demand Diels-Alder reaction yielding bioconjugates with molar activities that are satisfying for TAT (Poty et al. 2018c ). Nonetheless, a chelating ligand with the ability to quantitatively incorporate the 225 
III ion under conditions commensurate for radiopharmaceutical use (such as sub-micromolar ligand concentrations, mild ambient reaction temperatures, and fast reaction times), that also forms thermodynamically stable and kinetically inert complexes would be of high interest and utility in the field of 225 Ac TAT. Furthermore, access to myriad chelate options will allow greater flexibility during future discovery work of 225 Ac radiopharmaceuticals, since the radiometal-complex can be used to influence the pharmacokinetics of the overall construct, particularly for small molecule or peptide-based radiopharmaceuticals. In an effort to produce a viable alternative, an octadentate bispidine, H 2 bispa 2 (Comba et al. 2017) , and an 18-membered macrocycle, macropa (Thiele et al. 2017) , have been reported that show improved properties for 225 Ac radiolabeling, and to date are the only chelators that permit rapid, ambient temperature chelation (Deal et al. 1999; Chappell et al. 2000) .
The aims, herein, were to (1) determine the feasibility of producing 225 Ac via Isotope Separation On-Line (ISOL) at TRIUMF and (2) test the suitability of ISOL-derived 225 Ac (in terms of its (radio) chemical properties and amount of radioisotope produced) to drive radiolabeling studies and preclinical radiopharmaceutical development. Within the second aim, we sought to answer two questions: (2a) can the ISOL-derived 225 Ac be used to evaluate chelating ligands for Ac coordination; and (2b) is the 225 Ac-ISOL product produced in sufficient amounts to drive preclinical radiopharmaceutical development? In terms of radiopharmaceutical development, a DOTA-bioconjugate was chosen since DOTA is currently the industry standard in 225 Ac TAT. ISOL facilities have been used to produce medical radionuclides that are otherwise challenging to obtain (Dilling et al. 2014; dos Santos Augusto et al. 2014; Crawford et al. 2017a; Crawford et al. 2017b; Crawford et al. 2018 ). Herein we report for the first time the ISOLproduction of 225 Ac, at ISAC, TRIUMF's ISOL facility. The 225 Ac isolated from these experiments was used in radiolabeling studies with a class of picolinic acid ("pa") ligands developed in our laboratories (Price et al. 2014; Ramogida et al. 2015; Price et al. 2012; Spreckelmeyer et al. 2017) (Fig. 1 ) and compared to DOTA as well as macropa and Fig. 1 Ligand structures discussed in this work: macrocyclic commercial standard DOTA, previously reported ligands macropa and H 2 bispa 2 , acyclic picolinic acid "pa" ligands p-NO 2 -Bn-H 4 neunpa, H 6 phospa, H 4 CHXoctapa, and H 4 octapa, and DOTA-CycMSH bioconjugate (CCZ01048) H 2 bispa 2 (Comba et al. 2017; Thiele et al. 2017) . The "pa" chelating ligand family has demonstrated versatility for coordinating a number of imaging (e.g., gallium-67/68, indium-111, copper-64) and therapeutic isotopes (e.g., copper-64, lutetium-177, yttrium-90), making them extremely amenable for incorporation into a "theranostic" radiopharmaceutical. The octadentate and nonadentate "pa" ligands H 6 phospa (N 4 O 4 ) (Price et al. 2014) , p-NO 2 -Bn-H 4 neunpa (N 5 O 4 ) (Spreckelmeyer et al. 2017) , H 4 octapa (N 4 O 4 ) (Price et al. 2012; Price et al. 2013) , and H 4 CHXoctapa (N 4 O 4 ) (Ramogida et al. 2015) used in these radiolabeling experiments, were chosen because they were designed to incorporate larger metal ions such as actinium. Ac III has a documented ionic radius of 112 ppm (coordination number, CN 6) (Shannon 1976) and is likely suited to large polydentate chelators of high denticities. In addition, two DOTA-peptide conjugates, DOTA-D-Phe 1 -Tyr 3 -octreotide (DOTA-TOC) (Graf et al. 2014; Eppard et al. 2017 ) and DOTA-Cyclized α-melanocyte-stimulating hormone (DOTA-CycMSH, Fig. 1 ) (Zhang et al. 2017 ) was radiolabeled with our ISAC derived 225 Ac. Finally, a pilot in vivo study with the 225 Ac-DOTA-CycMSH conjugate on tumourbearing mice was performed to establish the feasibility of using ISOL-derived 225 Ac to drive preclinical radiopharmaceutical development. Malignant melanoma is the most lethal form of skin cancer, accounting for 75% of deaths from this type of cancer. Receptor-targeted radiopharmaceuticals for melanoma imaging and therapy are promising strategies for diagnosis and treatment. In particular, the melanocortin-1 receptor (MC1R) is highly expressed in 83% of malignant melanoma cell lines, and has low expression in normal tissues making it an attractive target for radionuclide therapy and imaging (Zhang et al. 2017; Raposinho et al. 2010) . Analogues of the tridecapeptide α-melanocyte-stimulating hormone (αMSH) have been studied extensively for MC1R-targeted imaging and less so for therapy. The most stable and successful analogues to date are based on lactam-bridged cyclized α-MSH (AcNle4-cyclo [Asp ]-NH 2 , or Nle-CycMSH hex ). Most recently our lab has developed a DOTA-CycMSH conjugate incorporating a cationic piperidine linker for positron emission tomography (PET) imaging with the positron-emitter gallium-68 ( 68 Ga, t 1/2 = 68 min) that exhibited promising ability to localize and internalize in melanoma cells, referred to herein as DOTA-CycMSH or CCZ01048 (Fig. 1) . The [ 68 Ga]Ga-CCZ01048 tracer exhibited high binding affinity to MC1R with sub-nanomolar K i values, rapid internalization into B16F10 melanoma cells, high in vivo stability in blood plasma, and exceptional PET image contrast in vivo with tumour-to-blood, tumour-to-muscle, tumour-to-bone and tumour-to-kidney ratios of 96.4 ± 13.9, 210.9 ± 20.9, 39.6 ± 11.9 and 4.0 ± 0.9, respectively, at 2 h post-injection (Zhang et al. 2017) . Given this 68 Ga-tracer's receptor binding affinity, rapid internalization, and low background organ uptake, we hypothesized that CCZ01048 would be a promising candidate for targeted alpha therapy with 225 Ac, and biodistribution studies were therefore conducted to evaluate the ability of CCZ01048 to deliver 225 Ac to B16F10 tumours in vivo.
Materials and methods
All solvents and reagents were purchased from commercial suppliers (Fisher Scientific, Sigma Aldrich) and used as received. Ultrapure HCl (TraceSELECT®) and NaOH (99.99% trace metal grade) was purchased from Sigma Aldrich; nitric acid (TraceMetal™ Grade) was purchased from Fisher Scientific. Branched DGA resin (N,N,N′,N′-tetrakis-2-ethylhexyldiglycolamide, 50-100 μm particle size) was purchase from Eichrom Technologies (Lisle, IL, USA). Picolinate-based ligands H 4 octapa, H 4 CHXoctapa, H 6 phospa, and p-NO 2 -Bn-H 4 neunpa were prepared as previously described (Price et al. 2014; Ramogida et al. 2015; Price et al. 2012) , as were H 2 bispa 2 and macropa (Comba et al. 2017; Thiele et al. 2017) . DOTA and human serum were purchased from Sigma Aldrich (St. Louis, MO). Pharmaceutical grade DOTATOC was purchased from ABX, DOTA-CycMSH was prepared as previously described (Zhang et al. 2017) . Deionized water (> 18 MΩ cm) was prepared on site using a Millipore Direct-Q® 3UV water purification system. All radioactivity measurements were performed using gamma ray spectroscopy on an Ntype co-axial high purity germanium (HPGe) gamma spectrometer (Canberra Industries) calibrated with a 20 mL 152 Eu and 133 Ba source. After thorough mixing, aliquots (5-100 μL) from a sample were removed and diluted to the 20 mL standard volume for measurement. Samples were counted at a distance at least 15 cm from the detector for at least 30 min or until peak areas were below 5%; dead time was kept below 5%. Spectra were analyzed using the Genie 2000 software package (version X, Canberra Industries), using 40 keV, 218 keV, and 440 keV gamma lines for 225 Ra, Ac were created using the isotope separation on-line (ISOL) technique in operation at TRIUMF's ISAC facility (Dilling et al. 2014) . Detailed descriptions of the collection of radioactivity from these beams is described elsewhere (Robertson et al. 2018; Crawford et al. 2017a; Crawford et al. 2017b; Crawford et al. 2018; Kunz et al. 2018) . Briefly, a uranium carbide target is bombarded with 9.8 μA of 480 MeV protons, which cause spallation, fission and fragmentation of the 238 U target atoms. Simultaneous heating of the target under vacuum results in the diffusion and effusion of volatile reaction products out of the target into the transfer tube/ionizer region. The reaction products, among them 225 Ra and 225 Ac, are ionized via surface or resonant laser ionization and extracted as a secondary particle beam with an energy of 20-40 keV, which is subsequently mass separated and delivered to experiments -in our case an aluminum implantation target for isotope collection. The resolving power of the ISAC mass separator is such that the delivered A = 225 beam contains isotopes of Fr, Ra, and Ac. Fr, and to some degree Ac and Ra, ionize in the ISAC surface ion source; however, higher ionization efficiencies can be obtained by means of element selective resonant laser ionization. Efficient laser ionization schemes for Ac and Ra can now be applied at ISAC simultaneously for co-implantation of Ac and Ra. After implantation, the aluminum target containing the implanted radioactivity was removed from the beamline and the 225 Ra and 225 Ac retrieved from the aluminum material by etching the surface of the aluminum with 0.1 M HCl (~0.5 mL) as described previously (Kunz et al. 2018) . Ramogida et al. EJNMMI Radiopharmacy and Chemistry (2019) The purification of 225 Ac from 225 Ra and other non-radioactive contaminants was adapted from previously reported methods for isolation of 225 Ac from solid thorium targets (Zielinska et al. 2007; Apostolidis et al. 2005; Radchenko et al. 2015; Horwitz et al. 2005) . Briefly, the recovered 225 Ra/ 225 Ac solution (0.1 M HCl,~0.5 mL) was diluted to 4 M HNO 3 (5 mL), and passed through a DGA column (35-40 mg of DGA branched resin in a 6 mm diameter reservoir, pre-conditioned with H 2 O (2 mL), 0.5 M HNO 3 (2 mL), and 4 M HNO 3 (2 mL)) (Horwitz et al. 2005) . Under these conditions, Ac III binds to the DGA while Ra passes through. The loaded DGA column was then washed with 4 M HNO 3 (4 mL). After air drying the column, the 225 Ac was eluted from the resin using 0.05 M HNO 3 (0.5 mL). This separation scheme is illustrated in Fig. 2 . The effluent (load fraction) containing 225 Ra II and the bulk of the non-radioactive Al III impurities was collected and retained to decay, allowing for additional grow-in of 225 Ac from 225 Ra. Approximately every 1-3 weeks, the purification procedure was repeated to isolate a new batch of 225 Ac.
The chemical purity of the 225 Ac product was assessed via inductively coupled plasma optical emission spectrometry (ICP-OES) and inductively coupled plasma mass spectrometry (ICP-MS) to quantify the presence of any stable cations that may compete with 225 Ac in radiolabeling reactions. Samples of both the initial solution containing 225 Ra and 225 Ac (before separation via DGA) and the final purified 225 Ac solution were analyzed for elemental composition using an Agilent 7700× inductively-coupled plasma mass-spectrometer (ICP-MS). All samples were prepared by drying on a hotplate, treated with concentrated HNO 3 and then again dried to convert all salts into the nitrate form. Samples were then diluted with a 1% HNO 3 , 0.05% HF solution containing 10 ppb Indium (internal standard). All acids used were sub-boiled to produce solutions containing a very low level of trace elements. Standard solutions were prepared from both mixed and single-element standards purchased from Inorganic Ventures Ac from the aluminum target was diluted with nitric acid (to 4 M HNO 3 ) and loaded onto a preconditioned DGA resin (Horwitz et al. 2005 225 Ac-complexes, a competition experiment was performed in the presence of excess human serum and the displacement of radioactivity from the chelator to serum proteins was tracked over the course of seven days. Endogenous metal-binding proteins in serum such as apo-transferrin and metallothionein can compete for and displace chelator-bound metal ions in vivo, preventing successful delivery of the radionuclide to the desired target. The 225 Ac-complexes were prepared using the radiolabeling protocols described above and added to an equal volume (170-180 μL) of human serum (stored at − 5°C and thawed at ambient temperature). At varying time points (0.5 h to 7 days), small aliquots (1-5 μL) were spotted on iTLC plates using Methods B or D, described above. Representative TLC radiochromatograms of a serum competition assay with ligand and control are presented in Additional file 1: Figures S2 and S3 . The stability of a radiometal-chelate complex is also often assessed by its ability to withstand transchelation in the presence of excess stable isotopes of the radiometal. Though this is an impossible experiment to perform with Ac since all Ac isotopes are unstable, lanthanum(III) has a similar ionic radius (103-116 ppm, CN = 6-9) and charge to actinium(III) and is often considered a chemical surrogate to Ac III . Using non-radioactive metal ions such as La III as a competitor for ligand complexation is a straightforward method to probe the kinetic off-rate of a pre-formed Ac III complex, since many ligands that bind Ac III may also efficiently complex La III . Herein, 225 Accomplexes were prepared using the radiolabeling protocols described above and combined with La(NO 3 ) 3 (0.1 M, 50 M equivalents compared to the ligand) and allowed to react at ambient temperature. At varying time points (1 h -7 d), aliquots of the competition reaction mixture (1-5 μL) were spotted on aluminum backed TLC plates and developed using the TLC methods described above.
Bioconjugate labeling studies and pilot in vivo studies with 225 Ac-DOTA-CycMSH
Preliminary radiolabeling studies with DOTATOC using ISOL-derived 225 Ac was performed. To prepare 225 Ac-labeled DOTATOC, 225 Ac III (37 kBq or 1.5 MBq) was added to a vial containing precursor (25 μg, in 25 μL deionized water) and ammonium acetate buffer (1 M, pH 7) to give a final ligand concentration between 19 and 9.8 × 10 − 5 M and heated at 85°C for 40 min. Reaction progress and RCYs were determined using iTLC method B (see 225 Ac radiolabeling studies and complex stability assays section).
To further demonstrate the utility of ISAC-ISOL derived 225 Ac and to explore the potential of novel 225 Ac-radiopharmaceuticals, preliminary radiolabeling and in vivo studies were conducted with a previously reported lactam bridge-cyclized α-melanocyte-stimulating hormone peptide conjugated to the DOTA chelator (DOTA-CycMSH or CCZ01048) (Fig. 1) .
To prepare 225 Ac-labeled CCZ01048, the entire 225 Ac fraction from a 225 Ra/ 225 Ac separation (see 225 Ac production and purification section) was evaporated to dryness and reconstituted with 25 μL of 0.05 M HNO 3 . This 225 Ac solution was combined with CCZ01048 (20-80 μg, 25 μL in deionized water) and an ammonium acetate buffer (1 M, pH 7, 35 μL). The reaction mixture was subsequently heated to 85°C for 30 min, and reaction progress and RCYs determined using iTLC Method B (see 225 Ac radiolabeling studies and complex stability assays section). More details regarding the selection of conditions for labeling CCZ01048 with ISACderived 225 Ac can be found in Additional file 1: Section S2.
Following the radiolabeling reaction for the non-blocked in vivo experiments, HPLC purification was performed to remove unbound 225 Ac III and to separate radiolabeled product from precursor to ensure high molar activity of the final product for preclinical biodistribution studies. The reaction mixture was separated by HPLC using a semipreparative column eluted with 22% acetonitrile containing 0.1% TFA for 225 Ac-CCZ01048 at a flow rate of 4.5 mL/min. The retention time of the 225 Ac-labeled peptide was 9.5 min, compared to 10.0 min for the unlabeled peptide. The collected radiolabeled peptide was diluted with deionized water and retained on a C18 SepPak cartridge (Waters, preconditioned with 5 mL ethanol and 10 mL deionized water) to remove acetonitrile and TFA. The purified peptide was eluted with ethanol and diluted with 0.9% NaCl saline. HPLC purification was not performed for the blocking studies, but instead the radiolabeling reaction was diluted with ammonium formate (0.05 M, 10 mL), loaded onto a pre-conditioned C18 SepPak to remove unlabelled 225 Ac III , and the purified peptide was eluted with ethanol and diluted with 0.9% NaCl. Quality control of both reactions was conducted by iTLC-SG developed in citric acid (0.05 M, pH 5); under these conditions unbound 2225 Ac III travels with the solvent front (R f = 1) while 225 Ac-bound to peptide remains at the baseline (R f = 0). Both 225 Ac tracers had radiochemical purity > 98%. To determine the final molar activities of the purified tracer prior to in vivo injection, an aliquot of known volume (5-10 μL) was counted on the HPGe gamma spectrometer, and 225 Ac activity per unit volume was calculated. In parallel, a known volume of final diluted tracer was analyzed using analytical HPLC eluted with 22% acetonitrile containing 0.1% TFA at a flow rate of 1 mL/min, and the amount of peptide was quantified by integrating the peaks in the UV-Vis spectra (at 220 nm) and comparing to a standard curve of the [La(CCZ01048)] complex. The retention times of the unlabeled peptide and La-complex were 11.4 and 10.8 min, respectively. The B16F10 melanoma cell line (Mus musculus) used in the tumour model was purchased from ATTC (CRL-6475), and handled as previously described (Zhang et al. 2017) . The cell line was confirmed pathogen-free by the IMPACT 1 mouse profile test (IDEXX BioResearch). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, StemCell Technologies) supplemented by 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified incubator containing 5% CO 2 . Cells grown to approximately 90% confluence were washed with sterile 1× PBS (pH 7.4), followed by trypsinization.
Biodistribution studies were performed using male C57BL/6 J mice. For tumour implantation, mice were anesthetized using isoflurane on a precision vaporizer (5% for induction, and 2% for maintenance) in 2.0 L/min of oxygen, and 1 × 10 6 B16F10 cells were implanted subcutaneously on the right back at the level of the forelimbs. Tumours were allowed to grow and reach approximately 9 mm in diameter and used for biodistribution studies. Mice were anesthetized, and injected with 12-20 kBq of 225 Ac-CCZ01048 prepared at either high molar activity (> 200 kBq/nmol for non-blocking, n = 4) or low molar activity (1.2 kBq/nmol for blocking studies, n = 4).
After injection, the mice were allowed to roam freely in their cages and sacrificed 2 h post-injection by CO 2 asphyxiation under isoflurane anesthesia. Cardiac puncture was promptly performed to recover blood, and the organs of interest were harvested, rinsed with 1× PBS, and blotted dry. Each organ was weighed, and the radioactivity of the collected tissue was measured using a calibrated gamma counter 931(Packard Cobra II Auto-gamma counter, Perkin Elmer, Waltham, MA, USA) using three energy windows: 60-120 keV (window A), 180-260 keV (window B), and 400-480 keV (window C). Counting was performed both immediately following sacrifice and after 7 days to ensure equilibrium of the 225 Ac decay chain (Note: secular equilibrium of 225 Ac with its daughters is reached at about 24 h; samples in this study were counted after 7 days due to availability of the gamma counter). Counts were decay corrected from the time of injection and total organ weights were used for the calculation of injected dose per gram of tissue (%ID/g). No differences were noted between the data; therefore, the biodistributions are reported using the data acquired using window A.
Results

Ac production and purification
Mass A = 225, singly-charged (+ 1) ion beams produced at TRIUMF's ISAC facility contained 225 Ra and 225 Ac intensities between 4.0 × 10 6 -1.6 × 10 8 and 3.8 × 10 6 -1.3 × 10 8 ions/s, respectively, depending on the state of the extraction electrode and the availability of the laser ionisation source. 225 Fr (t 1/2 = 4.0 min) was also present but decayed rapidly to 225 Ra. For durations between 13.3-80.7 h, the 40 keV ions beams were implanted into an aluminum disk to a depth of 15-25 nm as determined by SRIM (Ziegler et al. 2010) . Etching of the radioactivity from the aluminum target post-implantation with 500 μL of 0.1 M HCl resulted in 0.2-7.5 MBq of 225 .0 MBq of 225 Ac. A summary of the production runs is shown in Table 1 . One-step purification of 225 Ac from 225 Ra on the DGA column reliably yielded a pure 225 Ac product, free from parent isotope 225 Ra, with yields > 90% as determined by gamma ray spectroscopy. A second elution with an additional 0.5 mL of 0.05 M HNO 3 is typically able to recover the remaining 225 Ac. The overall purification yield of 225 Ac from the target solution was > 98%. Example results from a single separation are shown in Fig. 3 . The load fraction containing 225 Ra was retained and used as an 225 Ac generator, providing a supply of 225 Ac for nearly 3 months.
To quantify the amount of stable metal impurities present in the 225 Ac product that could compete with 225 Ac during radiolabeling reactions, the chemical purity of the 225 Ac was assessed via ICP-OES and ICP-MS. Modest values of aluminum with 7709 ± 1281 and 10175 ± 872 ppb (3.9 ± 0.6 and 5.1 ± 0.4 μg) were present in the first and Ramogida et al. EJNMMI Radiopharmacy and Chemistry (2019) second eluates, respectively, compared to 166,000 ppb (830 μg) present in the load fraction (Table 2 ). The~200-fold decrease of Al in the eluate 1 compared to the initial load solution suggests that the DGA resin does a satisfactory job of removing excess Al III from the 225 Ac III product with a separation factor of~10 2 ; however, an additional washing step may further decrease the amount of metal impurity, which may in turn positively impact radiolabeling yields. Calcium, iron, copper, nickel and zinc were found in the 225 Ac product (elute 1) with amounts of 1392 ± 208, 203 ± 20, 47 ± 12, 19 ± 6 , and 137 ± 21 ppb, respectively. If one assumes the entire solution of eluate 1 (0.5 mL) were to contain 10 MBq of 225 Ac, the nonradioactive impurities would account for 6970 ± 1158 atoms of aluminum, 847 ± 127 atoms of calcium, 88 ± 9 atoms of iron, 51 ± 8 atoms of zinc, 8 ± 2 atoms of nickel, and 18 ± 5 atoms of copper per atom of actinium. Of concern are the high M n+ :Ac III ratios of Al III , Fe III , and Ca II in the 225 Ac eluate, since the gold standard in actinium chelation, DOTA, also has a strong affinity for these metals (Clarke and Martell 1991) . Additional ICP-MS results for other elements (in ppb and μg) can be found in Additional file 1: Section S3. Table S1 ).
Previously published 225 Ac radiolabeling results with ligands (macropa) 2− and (bispa 2 ) 2− , (Comba et al. 2017; Thiele et al. 2017) , which were performed with the same source of 225 Ac are also plotted in Fig. 4 
